refractory nephropathy
Conditions
Interventions
Control group of refractory severe acute kidney injury:Routine basic treatment
intervention group of refractory severe acute kidney injury:Routine basic treatment and hUCB-MNCs transplantation
Control group of refractory immune nephropathy:Routine basic treatment
intervention group of refractory immune nephropathy :Routine basic treatment and hUCB-MNCs transplantation
Sponsors
The Second Xiangya Hospital, Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 70 years old; with full capacity to participate in the clinical trial and participate in the follow-up trial of this study; 2. Sign the informed consent form; 3. selected diseases: refractory severe acute kidney injury, immune nephritis; (1) Indications for refractory severe acute kidney injury: renal function did not return to baseline after 7 days of routine treatment, progressed to patients with acute kidney disease; renal biopsy diagnosed as acute tubular injury or necrosis; (2) Inclusion criteria for refractory immune nephropathy: 24 h urine protein quantitation 60 ml/min/1.73 m2, with renal function and urine protein no significant improvement after conventional basic treatment for 3 months in patients with primary glomerulonephritis. The pathological type of renal biopsy diagnosis was mainly limited to mesangial proliferative nephritis (including IgA nephropathy), membrane proliferative nephritis, and focal segmental glomerulosclerosis.
Exclusion criteria
Exclusion criteria: 1. Heart, lung, liver failure, due to severe anemia transfusion, or already diagnosed diseases (such as mental illness), for whom is difficult to complete a study for up to 1 year; 2. End-stage renal failure; 3. The patient or the guardian is unable or unwilling to sign an informed consent form; 4. With various infections within 4 weeks; 5. Subjects who are participating in other drug clinical trials; 6. The researchers believe that the study is not suitable for clinical trials for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum creatinine;Total urine protein;Cys-C; | — |
Secondary
| Measure | Time frame |
|---|---|
| Estimated glomerular filtration rate;Blood urea nitrogen;Serum uric acid;Serum albumin; | — |
Countries
China
Contacts
Public ContactShao-Bin Duan
Second Xiangya Hospital, Central South University
Outcome results
None listed